| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/21/2011 | US20110091456 Treatment of neurological conditions |
| 04/21/2011 | US20110091452 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies |
| 04/21/2011 | US20110091449 Isolation of Anti-Desmoglein 1 Antibodies by Phage Display of Pemphigus Foliaceus Autoantibodies |
| 04/21/2011 | US20110091448 Methods for regulation of stem cells |
| 04/21/2011 | US20110091445 Modulation of intestinal flora of hiv patients |
| 04/21/2011 | US20110091442 Novel compositions for preventing and/or treating lysosomal storage disorders |
| 04/21/2011 | US20110091441 Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof |
| 04/21/2011 | US20110091440 Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases |
| 04/21/2011 | US20110091435 Phytoestrogenic formulations for alleviation or prevention of hair loss |
| 04/21/2011 | US20110091423 Compositions and methods of use of ritonavir for treating hcv |
| 04/21/2011 | US20110091421 Methods of Novel Therapeutic Candidate Identification Through Gene Expression Analysis in Vascular-Related Diseases |
| 04/21/2011 | US20110091420 Injectable Sustained-Release Pharmaceutical Formulation and the Preparation Method Thereof |
| 04/21/2011 | US20110091418 Methods for treating viral infections using polyamine analogs |
| 04/21/2011 | US20110091417 Interleukin-22 Polypeptides, Nucleic Acids Encoding The Same And Methods For The Treatment Of Pancreatic Disorders |
| 04/21/2011 | US20110091415 Hydroxyethyl Starch-Containing Polypeptide Compositions |
| 04/21/2011 | US20110091412 Mutant interleukin-2 (il-2) polypeptides |
| 04/21/2011 | US20110091408 Methods of using fluoroalkyl phosphate compositions |
| 04/21/2011 | US20110091407 Polymer derived from linear polyethylenimine for gene transfer |
| 04/21/2011 | US20110091405 Composition and methods for promoting lush hair growth |
| 04/21/2011 | US20110091403 Oligosaccharide aldonic acids and their topical use |
| 04/21/2011 | US20110091392 Compositions for the treatment and prevention of infections of the oral cavity |
| 04/21/2011 | US20110091388 Use of pde7 inhibitors for the treatment of movement disorders |
| 04/21/2011 | US20110091387 Methods and compositions for reducing skin damage |
| 04/21/2011 | US20110091385 Substituted aryl piperidinylalkynyladenosines as a2ar agonists |
| 04/21/2011 | US20110091383 Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents |
| 04/21/2011 | US20110091380 Chlorotoxins as drug carriers |
| 04/21/2011 | US20110091377 Biomarkers for melanoma |
| 04/21/2011 | US20110091375 Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
| 04/21/2011 | DE202009017772U1 Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid Combination products with cytokine antagonist and corticosteroid |
| 04/21/2011 | DE102009049679A1 Pyrazolopyrimidinderivate Pyrazolopyrimidinderivate |
| 04/21/2011 | DE102009049505A1 Use of antimicrobial agent for preparing antiseptic for use in a disinfection method in which ultrasound is used simultaneously, where the disinfection method is e.g. wound healing, preoperative skin disinfection and surface disinfection |
| 04/21/2011 | DE102009049332A1 Medicinal substance, useful e.g. for treating hemorrhoidal disease, comprises lactulose, which is used for supplying nutrients to the mucous membrane of the colon, pH adjustment and stabilizing the physiological intestinal flora rectally |
| 04/21/2011 | DE102009048044A1 Verwendung von Magnolol oder Honokiol als antibakterielle, antimycotische, antiparasitäre oder antivirale Wirkstoffe Use of magnolol and honokiol as antibacterial, antifungal, antiparasitic and antiviral agents |
| 04/21/2011 | DE102009035109A1 Wundheilzusammensetzung Wound healing composition |
| 04/21/2011 | CA2782055A1 Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs |
| 04/21/2011 | CA2780741A1 Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| 04/21/2011 | CA2777920A1 Aptamer capable of binding to viral hemorrhagic septicemia virus |
| 04/21/2011 | CA2777856A1 Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof |
| 04/21/2011 | CA2777843A1 Treatment of suicidal ideation or behavior using inhibitors of nicotinic acetylcholine receptors |
| 04/21/2011 | CA2777835A1 Supercoiled minicircle dna for gene therapy applications |
| 04/21/2011 | CA2777816A1 Methods and compositions for novel liquid crystal delivery systems |
| 04/21/2011 | CA2777782A1 Sepiapterin reductase inhibitors for the treatment of pain |
| 04/21/2011 | CA2777775A1 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes |
| 04/21/2011 | CA2777762A1 Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon |
| 04/21/2011 | CA2777741A1 Antimicrobial compounds and methods of making and using the same |
| 04/21/2011 | CA2777739A1 Antimicrobial compounds and methods of making and using the same |
| 04/21/2011 | CA2777734A1 Antimicrobial compounds and methods of making and using the same |
| 04/21/2011 | CA2777699A1 Phospholipases, nucleic acids encoding them and methods for making and using them |
| 04/21/2011 | CA2777664A1 Macrocyclic integrase inhibitors |
| 04/21/2011 | CA2777565A1 Hematopoietic growth factor mimetic small molecule compounds and their uses |
| 04/21/2011 | CA2777563A1 N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| 04/21/2011 | CA2777561A1 Combination |
| 04/21/2011 | CA2777560A1 Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor |
| 04/21/2011 | CA2777546A1 Treating neurotoxicity associated with combinations of 5-fu or its prodrugs and dpd inhibitors |
| 04/21/2011 | CA2777537A1 Compositions and methods for mild sedation, anxiolysis and analgesia in the procedural setting |
| 04/21/2011 | CA2777518A1 Cgrp receptor antagonists |
| 04/21/2011 | CA2777509A1 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system |
| 04/21/2011 | CA2777448A1 Compositions for controlling varroa mites in bees |
| 04/21/2011 | CA2777418A1 Silyl polymeric benzoic acid ester compounds, uses, and compositions thereof |
| 04/21/2011 | CA2777384A1 Combination therapy treatment for viral infections |
| 04/21/2011 | CA2777373A1 Metal complexes of n-heterocyclic carbenes |
| 04/21/2011 | CA2777367A1 Reducing the risk of pathological effects of traumatic brain injury |
| 04/21/2011 | CA2777358A1 Emesis treatment |
| 04/21/2011 | CA2777305A1 Polymorphs of pardoprunox |
| 04/21/2011 | CA2777290A1 Process for the preparation of f-series prostaglandins |
| 04/21/2011 | CA2777283A1 Sulfoxide derivatives for the treatment of tumours |
| 04/21/2011 | CA2777113A1 Spirocyclic derivatives as histone deacetylase inhibitors |
| 04/21/2011 | CA2777043A1 Substituted piperidines that increase p53 activity and the uses thereof |
| 04/21/2011 | CA2777018A1 Novel method for preparing entecavir and intermediate used therein |
| 04/21/2011 | CA2777013A1 Marker associated with non-alcoholic steatohepatitis |
| 04/21/2011 | CA2777010A1 Anti-misuse solid oral dosage form provided having a modified specific release profile |
| 04/21/2011 | CA2776845A1 Aerosol formulations comprising a wetting agent to reduce particle deposition |
| 04/21/2011 | CA2776835A1 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
| 04/21/2011 | CA2776543A1 Inhibitors of bruton's tyrosine kinase |
| 04/21/2011 | CA2776457A1 Spiro-condensed cyclohexane derivatives as hsl inhibitors useful for the treatment of diabetes |
| 04/21/2011 | CA2776359A1 Improved medicinal aerosol formulations |
| 04/21/2011 | CA2776310A1 Pharmaceutical compositions |
| 04/21/2011 | CA2776028A1 Pyrrolo[2,3-d]pyrimidine compounds |
| 04/21/2011 | CA2775803A1 Combination |
| 04/21/2011 | CA2775732A1 High-purity rebaudioside d and applications |
| 04/21/2011 | CA2775266A1 Anti-cancer tamoxifen-melatonin hybrid ligand |
| 04/21/2011 | CA2774512A1 Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions |
| 04/21/2011 | CA2774250A1 C-linked hydroxamic acid derivatives useful as antibacterial agents |
| 04/21/2011 | CA2772995A1 Fused thiazolo and oxazolo pyrimidinones |
| 04/21/2011 | CA2771665A1 Co-crystals of tramadol and coxibs |
| 04/21/2011 | CA2767541A1 Inhibitors of filovirus entry into host cells |
| 04/21/2011 | CA2735343A1 Compositions that include anthocyanidins and methods of use |
| 04/20/2011 | EP2312309A2 Chromatography of metal complexes |
| 04/20/2011 | EP2312024A1 Polymorphisms predictive of anthracycline-induced cardiotoxicity |
| 04/20/2011 | EP2311980A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/20/2011 | EP2311979A1 Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer |
| 04/20/2011 | EP2311978A1 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 04/20/2011 | EP2311973A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 04/20/2011 | EP2311955A2 Osteoprotegerin binding proteins and their receptors |
| 04/20/2011 | EP2311949A2 Antisense compounds targeted to connexins and methods of use thereof |
| 04/20/2011 | EP2311881A2 Cripto binding molecules |
| 04/20/2011 | EP2311880A2 Cripto binding molecules |
| 04/20/2011 | EP2311875A1 Treatment with anti-VEGF antibodies |
| 04/20/2011 | EP2311850A1 Anti-cancer cyclopenta[g]quinazoline compounds |
| 04/20/2011 | EP2311849A1 Specific binding agents of human angiopoietin-2 |